HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Latest evidence from the world's longest running study on myopia management spectacle lenses reinforced the effectiveness of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology in continuing to significantly reduce myopia progression and axial elongation over 8 years 1
Findings from the randomized controlled trial, ASPECT, demonstrated that combining 0.025% atropine drops with DIMS spectacle lenses reduces axial elongation in myopic children 2
A first-of-its-kind concept trial showed that D.I.M.S. Technology may offer a protective effect against the development of myopia in pre-myopic preschool children and postpone the onset of myopia3
HOYA Vision Care (https://www.hoyavision.com/) today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results were presented as part of the company's 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART*, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, USA.
The latest findings from the world's longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full 8 years (n=11) of follow-up.1 This evidence demonstrates that wearing MiYOSMART* spectacle lenses continuously and for the long-term may improve myopia management outcomes.
Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care said 'This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest. These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for Eye Care Professionals and parents committed to protecting children's vision health for the future.'
The first 12-month data readout from the ASPECT randomized controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children.2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment.4
'Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child.' said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care.
A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in 5- and 6-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable. These promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research.3
'With myopia rising at an alarming rate worldwide, finding effective strategies to slow its progression have never been more urgent,' saidDr. Vlasak. 'With these studies, we continue to provide Eye Care Professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment. We are proud to deliver on our mission to protect the long-term vision and quality of life for every child through our evidence-backed myopia management innovations.'
For the abstracts presented at ARVO 2025, please visit https://www.hoyavision.com/visionary-knowlegde/blogs-and-article/conference-arvo-2025/
Product Disclaimer: *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250611607786/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
Aspect Appoints Elizabeth Del Ferro as Chief Growth Officer to Accelerate Growth and Go-to-Market Execution
Enterprise SaaS leader to oversee global sales and go-to-market operations as Aspect drives expansion in workforce optimization and intelligence BOULDER, Colo., August 20, 2025--(BUSINESS WIRE)--Aspect, a leader in workforce optimization and intelligence, announces the appointment of Elizabeth Del Ferro as Chief Growth Officer (CGO). In this role, Del Ferro will lead Aspect's global sales, GTM operations, and customer success and services – advancing the company's mission to empower complex frontline workforces with intuitive and intelligent technology. She will also lead the charge in reforging Aspect's international, channel and segment growth strategy, unlocking new revenue streams and strengthening their global footprint. Del Ferro brings more than two decades of enterprise software and SaaS experience, including revenue and growth leadership roles at Oracle, Genpact, as well as ServiceNow and Duck Creek, where she played a key role in IPO-stage go-to-market efforts. She is known for scaling high-performing teams, tightening operational rigor, and aligning go-to-market strategy with measurable business outcomes. "Elizabeth brings exactly the kind of execution depth and leadership discipline we need as we concentrate our efforts on accelerating high-impact execution in our core market," said Darryl Kelly, CEO of Aspect. "Her focus on scalable systems, customer outcomes, and sales performance will be critical as we advance our workforce optimization and intelligence strategy." "Aspect is tackling some of the most critical challenges to optimize labor with demand as well as the agent experience within the shifting multi-channel workforce," said Del Ferro. "And, because of that, we're expanding our enterprise footprint to deliver our industry leading solutions into other markets that face workforce optimization and intelligence challenges. The market opportunity is enormous, and I'm excited to help Aspect capture it." Del Ferro's appointment reinforces Aspect's commitment to disciplined execution and long-term growth. With continued investment in its platform, go-to-market capabilities, and customer experience, Aspect is building the foundation to lead the next era of intelligent workforce solutions. About Aspect Aspect is dedicated to building intuitive technology for a more effective and engaged workforce. Supported by its parent company, Alvaria Inc., which boasts over 50 years of leadership in workforce management technology, Aspect is a trusted partner for large global enterprises across key sectors, including financial services, airlines, automotive, insurance, retail, telecommunications, and utilities. Aspect Workforce™ is a WEM solution designed to confidently manage large teams and empower every employee. The platform simplifies scheduling, enhances forecasting, and tracks performance, fostering growth for teams and maximizing ROI for businesses. For more details, visit View source version on Contacts Gillian Grefé, Director of Brand Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
12 hours ago
- Business Wire
Aspect Appoints Elizabeth Del Ferro as Chief Growth Officer to Accelerate Growth and Go-to-Market Execution
BOULDER, Colo.--(BUSINESS WIRE)--Aspect, a leader in workforce optimization and intelligence, announces the appointment of Elizabeth Del Ferro as Chief Growth Officer (CGO). In this role, Del Ferro will lead Aspect's global sales, GTM operations, and customer success and services – advancing the company's mission to empower complex frontline workforces with intuitive and intelligent technology. She will also lead the charge in reforging Aspect's international, channel and segment growth strategy, unlocking new revenue streams and strengthening their global footprint. 'Aspect is tackling some of the most critical challenges to optimize labor with demand as well as the agent experience within the shifting multi-channel workforce,' said Del Ferro. Share Del Ferro brings more than two decades of enterprise software and SaaS experience, including revenue and growth leadership roles at Oracle, Genpact, as well as ServiceNow and Duck Creek, where she played a key role in IPO-stage go-to-market efforts. She is known for scaling high-performing teams, tightening operational rigor, and aligning go-to-market strategy with measurable business outcomes. 'Elizabeth brings exactly the kind of execution depth and leadership discipline we need as we concentrate our efforts on accelerating high-impact execution in our core market,' said Darryl Kelly, CEO of Aspect. 'Her focus on scalable systems, customer outcomes, and sales performance will be critical as we advance our workforce optimization and intelligence strategy.' 'Aspect is tackling some of the most critical challenges to optimize labor with demand as well as the agent experience within the shifting multi-channel workforce,' said Del Ferro. 'And, because of that, we're expanding our enterprise footprint to deliver our industry leading solutions into other markets that face workforce optimization and intelligence challenges. The market opportunity is enormous, and I'm excited to help Aspect capture it.' Del Ferro's appointment reinforces Aspect's commitment to disciplined execution and long-term growth. With continued investment in its platform, go-to-market capabilities, and customer experience, Aspect is building the foundation to lead the next era of intelligent workforce solutions. About Aspect Aspect is dedicated to building intuitive technology for a more effective and engaged workforce. Supported by its parent company, Alvaria Inc., which boasts over 50 years of leadership in workforce management technology, Aspect is a trusted partner for large global enterprises across key sectors, including financial services, airlines, automotive, insurance, retail, telecommunications, and utilities. Aspect Workforce™ is a WEM solution designed to confidently manage large teams and empower every employee. The platform simplifies scheduling, enhances forecasting, and tracks performance, fostering growth for teams and maximizing ROI for businesses. For more details, visit
Business Wire
14-07-2025
- Business Wire
Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of Bioprinted Tissue Therapeutics (BTTs) as a new category in regenerative medicine, today announced new preclinical data at ENDO 2025, the Endocrine Society's annual meeting held in San Francisco. The company presented an oral and poster presentation highlighting that Aspect's adrenal BTTs can restore adrenal function, following natural daily hormone rhythms and maintaining long-term performance in animal models of primary adrenal insufficiency. Primary adrenal insufficiency is a serious, life-threatening condition in which the adrenal glands fail to produce sufficient levels of essential hormones such as cortisol, a key regulator of the body's stress response. The current standard of care involves daily hormone replacement therapy, which does not fully replicate the body's natural circadian hormone rhythms and is associated with significant drug-related side effects. This can leave patients with a poor quality of life and at risk of ongoing health challenges, including potentially fatal adrenal crises. Aspect's adrenal BTTs were developed using the company's proprietary full-stack tissue therapeutic platform, which combines AI-powered bioprinting, computational design tools, therapeutic cells, and advanced biomaterials. In preclinical studies, adrenal BTTs containing human adrenal cells were implanted into adrenalectomized mice. These BTTs produced cortisol in response to adrenocorticotropic hormone (ACTH) stimulation—which is normally secreted from the brain—and followed the animals' natural circadian fluctuations in hormone levels. When exposed to high levels of injected ACTH, these mice demonstrated rapid increases in circulating cortisol, confirming that the adrenal BTTs were functionally responsive. In contrast, control animals receiving cell-free implants showed no significant cortisol levels and did not respond to ACTH stimulation. Importantly, adrenal BTTs remained functional in vivo throughout the study period of over six months and improved animal survival. 'Our research shows that Aspect's adrenal BTTs successfully replicate healthy human adrenal gland function by releasing cortisol in a pattern that follows the natural daily rhythms of hormone release and by responding appropriately to a stimulus that mimics a stress response,' said Sam Wadsworth, PhD, Chief Scientific Officer at Aspect Biosystems. 'These results demonstrate that our off-the-shelf, implantable cell therapy can work in harmony with the body's physiology and has real potential to serve as a functional cure for primary adrenal insufficiency." 'At Aspect, we're making breakthrough progress with our Bioprinted Tissue Therapeutics platform to restore complex biological functions across a range of serious endocrine and metabolic diseases,' said Tamer Mohamed, Chief Executive Officer of Aspect Biosystems. 'This latest advance in primary adrenal insufficiency, a rare and life-threatening condition with limited treatment options, showcases the potential of a bioengineered cell therapy to recreate natural hormone function and deliver a truly disease-modifying solution. This reflects our mission to develop regenerative medicines capable of achieving functional cures for patients with serious and underserved diseases.' About ENDO Hosted by the Endocrine Society, ENDO is the leading global meeting on endocrinology research and clinical care. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions. Learn more at About Aspect Biosystems Aspect Biosystems is a biotechnology company pioneering the development of Bioprinted Tissue Therapeutics (BTTs) to transform how we treat some of the most elusive diseases. Aspect's BTTs are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of BTTs across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect's pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity. For more information, please visit and follow on LinkedIn.
